Skip to content

Respiratory Virus Infections in Acute Heart Failure

Respiratory Virus Infections in Hospitalized Patients With Acute Heart Failure Syndrome: A Prospective Multi-center Observational Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06967441
Enrollment
360
Registered
2025-05-13
Start date
2025-04-07
Completion date
2028-12-31
Last updated
2026-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure Syndrome

Keywords

acute heart failure, respiratory virus

Brief summary

Patients admitted to the cardiology department with acute heart failure who have a nasopharyngeal respiratory virus PCR test performed within 72 hours of admission will be enrolled in the study cohort. The detection rate of respiratory viruses including influenza virus, RSV, and coronavirus will be analysed. The investigators will also look for seasonal changes in the frequency of respiratory viruses and differences in the clinical presentation of heart failure based on respiratory virus infection.

Interventions

None listed

Sponsors

Minjae Yoon
Lead SponsorOTHER
Samsung Medical Center
CollaboratorOTHER
Seoul St. Mary's Hospital
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum

Inclusion criteria

* Adult aged 19 years or older admitted to the cardiology department with acute heart failure * NT-proBNP \>300 pg/mL * Clinician judgement of possible respiratory viral infection (fever \>38 degrees or cough, respiratory symptoms such as sputum or consolidation on x-ray or CRP \>5 mg/dL) * Patients who have a nasopharyngeal swab for respiratory virus PCR test performed within 72 hours of admission for any of the 3 reasons

Exclusion criteria

* Patients with a clear other cause of acute heart failure (ex. ACS, bradycardia requiring a pacemaker, uncontrolled tachycardia, uncontrolled severe hypertension (SBP \>180mmHg or DBP \>110mmHg), haemoglobin \<7g/dL or AHF precipitated by medication non-adherence) * If the cause of pulmonary oedema is prominently attributed to exacerbation of CKD * If there is a clear other source of infection that can explain the fever

Design outcomes

Primary

MeasureTime frameDescription
Respiratory virus PCR detection rateWithin 3 days of admissionRespiratory virus PCR detection rate (especially RSV, influenza virus) in acute HF

Secondary

MeasureTime frameDescription
Days of hospitalizationFrom admission to discharge during index hospitalization (upto 30 days)Days of hospitalization
Rate of ICU care or ventilationFrom admission to discharge during index hospitalization (upto 30 days)Rate of ICU care or ventilation
In hospital mortalityFrom admission to discharge during index hospitalization (upto 30 days)In hospital mortality
mortality12 monthafter discharge, 12-month mortality
Rehospitalization12monthafter discharge, 12-month rehospitalization

Countries

South Korea

Contacts

CONTACTMinjae Yoon, MD
minjae1677@gmail.com+82-10-6334-1917

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026